Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
← catalyst calendarNCT06993610 · readout ≤ 103 d
Sponsored by Zura Bio Inc (industry) · ZURA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
225estimated
Sites
61
Countries
Canada, Germany, Hungary +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-16 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa (HS)
Interventions
- Biological: Tibulizumab Dose A
- Biological: Tibulizumab Dose B
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OF[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks
measured Week 16
Permalink · ZURA's whole pipeline · Catalyst calendar · Every registered study · What changed